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ABSTRACT 
Objective: This study was designed to evaluate the use of bentonite in the formulation of sustained-release tablets containing alogliptin benzoate 
after granulation.  
Methods: Bentonite was used for preparing tablets after granulation. The prepared tablets were tested for their pharmacopeial requirements. 
Further, a high-performance liquid chromatography (HPLC) method was developed to assess the release pattern of alogliptin from the tablets. 
Besides, differential scanning calorimetry (DSC), fourier transform infrared spectroscopy (FTIR), and powder X-ray diffraction (XRD) were used for 
evaluating the compatibility the drugs and bentonite. Finally, the release from the tablets was tested using the paddle apparatus.  
Results: The FTIR and DSC did not show any interaction between the drug and the excipient in contrast to the powder-XRD pattern, which showed a 
shift for montmorillonite crystal peak. This shift was interpreted by increasing in the spacing of the crystalline structure of montmorillonite. However, 
the results of pharmacopeial tests showed that the prepared tablets comply with the compendial requirements, In addition, the release profiles of these 
tablets with aid of hydroxypropyl methylcellulose (HPMC) as a binder revealed a sustained release of alogliptin. Furthermore, the fitting of release data 
showed that the release from these tablets followed Fickian diffusion that alogliptin released by diffusion from bentonite gel matrix.  
Conclusion: Bentonite was successfully used for producing sustained-release tablets of alogliptin. However, maintaining the crystal structure of 
montmorillonite was essential for building the gel structure of bentonite and releasing the drug in a controlled manner.  
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INTRODUCTION  
Alogliptin gained approval for the first time in 2010 in Japan for the 
treatment of type 2 diabetes mellitus (T2DM). It is a short-acting 
dipeptidyl peptidase-4 (DPP-4) inhibitor that works by inhibiting 
the DPP-4 enzyme to extend the plasma level of glucagon-like 
peptide-1 (GLP-1) [1]. Alogliptin benzoate has a short half-life of 1-2 
h; therefore, it can be given twice a day [2].  
The oral route of drug delivery is the most convenient. On the other 
hand, it has few limitations such as poor patient compliance related 
to oral side effects; probabilities of dose missing, plasma level 
fluctuations by multiple drug regimen, which increases the incidence 
of side effects as well as the overall cost of treatment [3, 4]. 
However, these inconveniences can be resolved either by 
derivatization of the drugs to obtain new drugs with a longer half-
life and large therapeutic indices or by formulating modified release 
and targeted dosage forms for existing drugs [3, 5]. The first strategy 
has several difficulties whereas the second is used broadly [6]. 
However, for the good candidate drugs to be formulated into 
modified release dosage form, they should be easily absorbed from 
the GIT (Gastro-Intestinal Tract) and have short half-lives [7]. 
There are three main terms used for modified release drug delivery 
systems: sustained-release tablets, delayed-release tablets, and 
pulsatile-release tablets. Sustained-release or extended-release 
dosage forms are defined as a dosage form that slows the release 
rate of a drug [8-10]. 
The European Pharmacopoeia (2002) recognized bentonite as a 
naturally occurring mineral clay consisting mainly of 
montmorillonite which is alkaline aluminum silicate Al2O3.4SiO2 . 
H2
However, very few papers reported on using bentonite as an 
excipient for formulating tablets. Bai et al. 2010 reported the use of 
bentonite as a disintegrating agent [15]. Moreover, Lin et al., 2002 
intercalated 5 fluorouracil into montmorillonite to produce a 
composite of 5 fluorouracil/montmorillonite to treat colorectal 
cancer [16]. Ranitidine in a study was intercalated with 
montmorillonite by ion exchange process; then the resulted particles 
were coated with Eudragit. Ranitidine was released from these 
particles in a controlled manner [17]. Bounabi et al. intercalated 2-
hydroxyethyl methacrylate monomer into the interlayer spaces of 
sodium montmorillonite (MMT) nanoparticles [18]. Further, Olivera 
and his research group integrated olanzapine into montmorillonite 
(MMT) in a combination of alginate and xanthan gum biopolymers to 
improve the formulation of bionanocomposites [19]. Finally, 
recently, Alkrad et al. investigated the use of bentonite as an 
excipient in preparing sustained release tablets by direct 
compression [20]. However, the powder had a poor flowability 
which limits the use of bentonite as an excipient by direct 
compression [21, 22]. 
O and can be swollen with a little water forming a pliable mass 
[11]. Wet silicate is not absorbed in systemic circulation; so, 
bentonite is safe for oral delivery. Furthermore, the American food 
and drug administration did not put a restriction for its use in 
foodstuffs (CFR-Code of Federal Regulations Title 21, Part 184) [12]. 
Due to the reactivity of montmorillonite, bentonite has been used as 
an adsorbent for toxic materials. Its negative charge allows it to bind 
cadmium, lead, and other toxins. Bentonite is very alkaline, which 
helps to neutralize the acid in the stomach [13, 14]. 
This present study aims to develop a new formula for preparing 
sustained release alogliptin tablets using bentonite after granulation. 
MATERIALS AND METHODS 
Materials 
Alogliptin benzoate was generously gifted from the United 
Pharmaceutical Industry (Amman, Jordan). Sodium sulfate 
(anhydrous) and bentonite were purchased from Sigma-Aldrich 
(Steinheim, Germany). Sodium hydroxide and potassium dihydro 
phosphate (KH2PO4) were all purchased from Merck (Darmstadt, 
Germany). Acetonitrile HPLC grade was purchased from MACRON 
(China). Hydroxypropyl methylcellulose (HPMC) was purchased from 
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Yangzhou WeiKem Chemical Co., Ltd (China). Ortho-phosphoric acid 
was purchase from Frutarom (bekuhaimstalar, UK). Microcrystalline 
cellulose (Avecil®
Methods  
101) was purchased from FMC (Brussels, Belgium).  
Granulation and tableting  
Bentonite (B) and alogliptin benzoate (AB) were sieved separately 
through a 45µ sieve. AB, B, and a binder were mixed thoroughly 
using a pestle and mortar for batch size 10 g. The amount of each 
component was calculated for preparing 400 mg tablets (table 1). 
The tablets were prepared from granules prepared either by wet or 
dry granulation. The sieved granules were mixed with 1 % 
magnesium stearate before being manually compressed in an 8 mm 
die of a single press machine-model AR 400E made by Erweka 
(Heusenstamm, Germany). 
Wet granulation: Water was sprayed over the powder mix then the 
wet mass was forced through stainless steel sieve (Ø 200 mm, rim 
size 50 mm) with aperture size 0.355 mm. Then, the formed 
granules were transferred into an oven and, then, they were dried 
overnight in an oven at 56 °C.  
Dry granulation: large tablets (die size 18) (slugs) were prepared from 
a mixture of alogliptin and Avicel®
 
101 (microcrystalline cellulose 
(MCC)). The large tablets were milled in a pestle and mortar then 
sieved using a sieve with an aperture size of 0.355 mm [22, 24]. 
Table 1: Composition of formulated tablets 
Formulation AB (mg) Bentonite (mg) Binder (mg) Lubricant 1% (mg) Total amount (mg) 
HPMC5% 25 351 20 4 400 
HPMC10% 25 331 40 4 400 
HPMC20% 25 291 80 4  400 
HPMC30% 25 251 120 4  400 
Avecil10% 25 331 40 4 400 
PEG4000 5%  25 351 20 4 400 
 
Spectroscopy-measurements  
Differential scanning calorimeter (DSC), Fourier transform infrared 
spectroscopy (FTIR), and X-ray diffraction (XRD) were used 
frequently in research to detect any interaction between the drug 
and the excipients [24-26].  
Differential scanning calorimeter (DSC) measurements 
The DSC thermograms of pure alogliptin, HPMC, a physical mixture 
of milled alogliptin with bentonite and milled granules composed of 
bentonite, alogliptin, and 20% HPMC were recorded using a 
differential scanning calorimeter (model 204 F1 phoenix) made by 
Netzsch-Gerätebau GmbH, Postfach in Germany. The thermograms 
were measured between 25 and 300 °C at a heating rate of 10 
°C/min under a dry nitrogen flow of 20 ml/min. The DSC 
thermograms were recorded in triplicate. DSC calibration for the 
instrument was done, using indium (10 mg, 99.999 % pure, melting 
point 156.60 °C, the heat of fusion 28.40 J/g). 
Fourier transform infrared spectroscopy (FTIR) measurements  
FT-IR spectrometer (PerkinElmer UATR Two, Li600301 spectrum 
made in Llantrisant, UK) was used to test the compatibility between 
the alogliptin and bentonite. The spectra for each of bentonite, 
alogliptin, HPMC and alogliptin, bentonite, and 20%HPMC granules 
were measured between 450 and 4000 cm-1
X-ray diffraction (XRD) characterization  
. 
The X-ray diffraction (XRD) patterns of bentonite, a mixture of 
alogliptin and bentonite, and granules of alogliptin, bentonite, and 
HPMC (20%) were obtained by a Shimadzu XRD-7000 diffractometer 
equipped with graphic monochromator CuKα radiation and a fixed 
power source (40 KW, 30 mA). The scan rate was 0.5 ˚ (2θ) min−1
Flowability measurement 
. 
A volume of 10g of each powder was filled in a 25 ml measuring 
cylinder that was tapped 15 times or until there was no change in 
the powder volume [23]. The CARR’s index (CI) and Hausner Ratio 
(HR) indicators were estimated according to the following equations 
(Eq. 1 and 2) [24-26]: 
 …… (Eq. 1) 
 ……. (Eq. 2) 
Measuring of the friability 
The friability test was performed according to the USP34 [23]. 
Briefly, 10 tablets were weighed and put in the Friabilator (Erweka 
TAR20, Heusenstamm, Germany). The device was turned on at 25 
rpm for 4 min. After tumbling, the tablets were removed, de-dusted, 
and reweighed accurately. The difference ratio was calculated by 
using the following equation (Eq. 3) [24-25]. 
 …… (Eq. 3) 
Where WI is the initial weight of the tablets and the WF is their 
weight after the friability test. 
Hardness measurement 
The hardness of ten tablets was measured by using Erweka TBH30 
(Germany). 
Dissolution profile  
Dissolution profiles over 24 h were established with aid of a USPII 
dissolution tester (Hanson Research SR6). The apparatus was run at a 
rotation rate of 50 rpm and 37 °C. The dissolution test was evaluated 
in 900 ml potassium dihydrogen phosphate buffers at pH 6.7 [23]. 
Samples with volume of 2 ml were removed after 1, 2, 3, 4, 5, 6, 7, and 
24 h of starting the test. The Samples were filtered using a 0.45 µ filter 
before being assayed by using the developed HPLC method. 
High-pressure liquid chromatogram (HPLC) assay 
A Thermo Scientific Chromatographic system (Dionex Ultimate 
3000-model) connected with a diode array detector (Germany) was 
used for quantifying alogliptin. A mobile phase consisting of a 
sodium sulfate anhydrous with ortho-phosphoric acid buffer pH 2.3 
[23] and acetonitrile (200:800) at a flow rate of 1.5 ml/min with a 
total runtime of 13 min was used to separate the samples in a C18 
column system (250 × 4.6 mm), supplied by Thermo scientific. The 
injection volume for alogliptin benzoate was 100μl and the detection 
was carried out at a wavelength of 254 nm. 
Statistical evaluation 
The tests were triplicated then the means and standard deviations 
were calculated. The similarity of the results was tested by t-test with a 
confidence interval of 95% (P  < 0.05) using (Origin60® lab program). 
RESULTS  
Flowability of granules  
Before and after tapping the different dry granules and the physical 
mixture of alogliptin and bentonite, the bulk densities were measured 
using a measuring cylinder. The measuring cylinder was tapped 
enough over a horizontal surface until no change of the powder 
volume was observed; the tapped density, then, was calculated. Out of 
the bulk density and tapped density, each of CARR’s and Hausner 
indexes was estimated, as shown in table 2 below: 
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Table 2: The estimated flowability by CARR’s index and hausner ratio 
Formulations Bulk density (g/ml) Tapped density (g/ml) CARR’s index (%) Hausner ratio 
Alogliptin and Bentonite mixture 0.43±0.003 0.71±0.005 36.3±0.26 1.57±0.26 
HPMC5% 0.44±0.003 0.51±0.004 14.81±1.17 1.17±0.11 
HPMC10% 0.45±0.003 0.54±0.004 16.63±1.20 1.2±0.12 
HPMC20% 0.53±0.004 0.64±0.005 16.6 1.±1.19 1.19±0.12 
HPMC30% 0.44±0.003 0.52±0.004 14.81±1.17 1.17±0.11 
AVICEL10% 0.45±0.003 0.55±0.004 21.05±1.27 1.27±0.15 
PEG 4000 0.42±0.003 0.6±0.004 29.99±1.43 1.43±0.22 
mean±SD, n=3 
 
Table 3: The hardness and friability of prepared tablets 
Formulation Hardness (N) Friability (%) 
HPMC5% 135±7.071 0.42±0.02 
HPMC10% 115.5±6.363 0.14±0.01 
HPMC20% 142.5±17.677 0.66±0.04 
HPMC30% 280±14.142 1.97±0.11 
mean±SD, n=3 
 
The results in table 2 show that the non-granulated physical mixture 
of alogliptin and bentonite had a poor flowability. However, the 
flowability was improved after granulation. 
Hardness and friability of the tablets  
The friability and hardness of the prepared tablets were evaluated. 
The calculated mean values and standard deviations are presented 
in table 3. 
The results of friability revealed that the tablets passed the 
pharmacopeial requirements except for HPMC30%, which showed a 
higher friability. Meanwhile, the tablets complied with a test of 
uniformity of mass; no tablet deviates from 5% of an average mass 
of 20 tablets (398±4.1) which were weighed individually. 
Furthermore, the hardness of tablets was relatively high; this 
reflects a high mechanical strength. However, the hardness 
decreased when the concentration of HPMC increased from 5 to 
10%, then increased again when the concentration was increased 
from 10 to 20 then 30%. On the other hand, the friability decreased 
with the increase of HPMC content. 
FTIR-measurements  
The measured spectra of each of alogliptin (fig. 1), HPMC, bentonite, 
and prepared granules from the previous mix (with HPMC 20%) are 
represented in fig. 2 below. FTIR-spectrum of the bentonite powder 
showed a band at 1021 cm−1 which is related to the stretch 
vibrations of Si-O in the Si-O-Si groups of the tetrahedral sheet. 
Besides, the bands at 524 and 464 cm−1
 
 are caused by Si-O-Al 
(octahedral sheet) and Si-O-Si bending vibrations [23-25]. 
 
Fig. 1: Structure of alogliptin benzoate 
 
The alogliptin bands of the spectrum did not appear in the spectrum 
of the granules, which showed only the bands of bentonite. However, 
the spectrum of bentonite did not change after granulation, which 
indicates that the drug did not interacts with bentonite. 
Furthermore, the assignment of the different bands of bentonite and 
alogliptin are tabulated in table 4 [27-29]. 
 
 
Fig. 2: FTIR-spectra of each of alogliptin, hydroxypropyl 
methylcellulose (HPMC), bentonite, and the prepared granules 
of previous components 
 
Table 4: Some bands of FTIR spectrum of alogliptin and possible 
related groups 
Wavenumber (cm-1 Bond ) 
3356 N-H stretching  
2977 O-H of carboxylic acid stretching  
1630 N-H bending 
1599 Carbonyl in the purine ring  
1451 C-H bending  
1365 C-N stretching of the aromatic ring  
1240 C-N stretching of the amine group  
1521 C=C stretching 
1623 C=O stretching  
718 C-H bending 
 
The bands of alogliptin did not appear clearly in the granules that 
the content of alogliptin in the mixture is very low. 
DSC measurements  
The DSC thermograms were taken to identify any possible 
interaction between alogliptin and bentonite. The measured 
thermograms are represented in fig. 3. 
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Fig. 3: DSC-thermograms of alogliptin, alogliptin, and bentonite 
physical mixture, HPMC, and prepared granules of alogliptin 
with aid of HPMC (20%). Conditions: samples heated from 30 to 
210 °C; heating rate: 10 °C/min 
 
However, the thermogram of alogliptin in the physical mixture of 
alogliptin and bentonite did not show any change in comparison to 
the thermogram of pure alogliptin. Hence, there is no interaction 
between bentonite and alogliptin. Moreover, the peak of alogliptin 
did not appears in the thermogram of the granules, which may be 
related to the low content of the drug. 
Powder-XRD-measurements 
Pure bentonite, milled bentonite, alogliptin granules, and milled 
bentonite, alogliptin, and HPMC granule were scanned within the 
range of 2-110 deg at a speed of 2θ/min. The XRD patterns of the 
samples are given in fig. 4. The XRD pattern of bentonite showed 
that bentonite contains mainly montmorillonite (Si3.74 Al2.03 
Fe0.03 Mg0.02 • O11) [30-32]. Other minerals were found to be 
quartz, cristobalite albite. However, the XRD pattern of the mixture 




Fig. 4: XRD patterns of bentonite, bentonite-alogliptin granules and 
bentonite-alogliptin-HPMC mixture (granules with HPMC (20%)) 
 
HPLC-method  
Alogliptin showed a retention time of 5.29±0.1 by HPLC-method (fig. 
5). A calibration curve was plotted for concentrations between 0.01 
and 0.1 mg/ml using HPLC (fig. 5) to estimate the released drug in 
dissolution tester and plotting the release profile. The equation of 
calibration line equation was y = 458x+0.6 with a correlation 
coefficient (r) of 0.99963. According to the European pharmacopeia, 
the ratio of the height of the peak of the lowest quantifiable amount 
(LOQ) to the high of noise signal should be higher than 9. The high 
ratio of the lowest concentration (0.01 mg/ml) to the noise was 
much higher than 9, which means that the detection limit is much 
lower than 0.01 mg/ml [11]. 
 
 
Fig. 5: Chromatogram of Alogliptin Using HPLC-method 
 
 
Fig. 6: Dissolution profiles of alogliptin from 5, 10, 20 and 30% HPMC bentonite tablet (mean±SD, n=3) 
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The dissolution rate of alogliptin from the tablets  
Many formulations were developed using different binders such as 
microcrystalline cellulose, PEG4000, starch, and hydroxypropyl 
methylcellulose (HPMC). The prepared tablets disintegrated rapidly 
except prepared tablets with aid of HPMC. The content of HPMC was 
increased gradually to detect the effect of HPMC on the dissolution 
rate of the drug from the tablets.  
The removed samples from the dissolution medium were analyzed 
using HPLC-method. The cumulative percentage released amounts 
against time graphs were plotted to establish the release profiles for 
a period of 24 h. (fig. 6). 
Fig. 6 shows that the release rate decreased with increasing HPMC 
content from 5 to 20% and increased when the content was 30%. 
For estimating the release model which the drug follows, the 
correlation coefficient (r) of cumulative percentage release amount 
of alogliptin against the time and the square route were estimated 
for 7 and 24 h. using Origin60®
 
 program; the results tabulated in 
table 5. 
Table 5: Calculated correlation coefficients for release data 
Formulation Zero-order 7h Zero-order 24h Fickian 24h 
R SD % R SD % R SD % 
HPMC5% 0.979  0.307 0.938 0.711 0.993 0.234 
HPMC10% 0.985 0.404 0.967 0.904 0.993 0.427 
HPMC20% 0.990 1.353 0.953 2.842 0.980 1.853 
HPMC30% 0.966 1.620 0.966 1.495 0.980 1.155 
 
The correlation coefficient for the fitted data was higher for the 7h. in 
comparison to 24h in the case of the zero-order release model. 
However, for the Fickian release model in comparison to zero-order, 
the correlation coefficient was higher. As there are no approved 
marketed sustained release alogliptin tablets, it was not possible to 
compare the performance of developed tablets with a reference. 
Furthermore, as the developed alogliptin tablets using bentonite-free 
HPMC were disintegrated and did not show a sustained release, it was 
not possible to estimate a correlation coefficient for these tablets. 
DISCUSSION  
Bentonite is not an expensive excipient in comparison to other 
matrices which are usually used to retard the release of drugs from 
tablets. The mixture of bentonite and alogliptin has poor flowability, 
which is the main hindrance of the direct compression [21, 22]. 
However, by granulation, it was possible to improve the flowability 
of the mixture [33]. On the other hand, binders are important for 
building the mechanical strength of granules and tablets [34]. Hence, 
different binders were used to granulate the mixture of drug and 
bentonite. The prepared tablets from granules prepared without 
binder disintegrated rapidly. Further, bentonite did not build a gel 
structure in dissolution medium when other binders such as Avicel 
and PEG4000 were used. 
DSC and FTIR are used frequently in pre-formulation studies to 
evaluate any possible interaction in prepared mixtures for preparing 
tablets [35-36]. FTIR and DSC measurements did not reveal any 
interaction between bentonite and alogliptin. However, XRD 
patterns showed a change in the crystalline structure of bentonite 
when granulated with alogliptin; this explains the disintegration of 
tablets in the presence of alogliptin. This effect has appeared by 
shifting the peak of montmorillonite crystal to a lower angle in the 
XRD pattern of alogliptin and bentonite granules. This may be due to 
the increase in the spacing of the crystalline structure of 
montmorillonite which is responsible for building the gel structure 
of bentonite [19]. The shift was a bit low in the case of granules 
made of bentonite, alogliptin, and HPMC (20%). This effect can be 
attributed to benzoate in alogliptin benzoate structure in a similar 
way to the reported effect of hydrochloric acid in the dissolution 
medium or the structure of the drug such as in the case of metformin 
HCl on the crystal structure of montmorillonite [20,37]. However, 
the presence of HPMC could maintain the property of bentonite for 
building gel structure in an aqueous medium. 
However, the other binders could not maintain the gel structure after 
hydration in the dissolution medium. Hydroxypropyl methylcellulose 
(HPMC) is a binder as well as one of the most important hydrophilic 
ingredients for preparing hydrogel matrices [38-40]. Paudel et al. 
reported that the lowest concentrations for Fickian release for 
different HPMC grades are 20, 15, and 11 % for K4, K15, and K100, 
respectively [41]. However, the formulated tablets showed sustained 
release up to a concentration of HPMC 5%; hence the sustained release 
can be related to bentonite, not to HPMC.  
The high mechanical strength is useful in preparing sustained-
release tablets [42]. The prepared tablets showed a high mechanical 
strength in general. This hardness was increased with increasing 
HPMC content. The high mechanical strength was not useful for 
building the gel structure of bentonite in the case of using avecil®
CONCLUSION  
 
and PEG4000 or slowing the release of the drug.  There are many 
strategies for designing sustained-release tablets. Some designs 
depend on erosion, permeation, or slow dissolution [5]. It is 
assumed that the sustained release of alogliptin is achieved by 
diffusion through the matrices not by the erosion, as the tablets 
swelled, maintained their integrity, did not disintegrate and their 
volume did not decrease during the dissolution test. This 
assumption was confirmed by the results of the data fitting of 
alogliptin release from bentonite and that it follows Fickian diffusion 
through the matrix [26, 38, 33]. 
Bentonite was used successfully in preparing sustained-release 
tablets containing alogliptin. However, this was possible only with 
aid of hydroxypropyl methylcellulose (HPMC). Furthermore, this 
study revealed the effect of benzoate on the crystalline bentonite 
structure and, as a result, the building gel structure of bentonite in 
water was hindered. Different used binders did not help to maintain 
the gel structure except by using HPMC. Increasing the 
concentration of HPMC didn’t improve the linearity of the constant 
release. Using powder-XRD was possible to detect the change in the 
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